Bristol Myers Squibb Company
NEWS
A roundup of last week’s top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more.
Genentech announced new data related to its investigational CD20xCD3 T-cell engaging bispecific antibody intended to treat relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
Johnson & Johnson and Momenta Pharmaceuticals have filed a patent infringement lawsuit over a generic multiple sclerosis drug developed by India-based Natco, Gland Pharma and Mylan.
This summer, BioSpace will release a series of reports looking at the current state of diversity and inclusion in the life sciences.
The American Society of Clinical Oncology and the Association of Community Cancer Centers are combining their efforts to increase racial and ethnic diversity in clinical trials.
BridgeBio Pharma and its affiliate Phoenix Tissue Repair announced positive data from their Phase II clinical trial for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).
Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.
Pfizer with Headlands Research plans to launch new clinical trial sites in areas that have highly diverse populations.
The FDA has a few target action dates for the end of the month, although PDUFA dates can sometimes seem like a moving target.
JOBS
IN THE PRESS